期刊文献+

12例中心型肺癌心包内处理血管的全肺切除术诊治体会 被引量:3

下载PDF
导出
摘要 目的 探讨心包内处理血管的全肺切除术手术方法的安全性和可行性。方法 对于标准全肺切除术难以切除的 12例中心型肺癌行切开心包 ,在心包内处理血管的全肺切除术。结果 全组无手术死亡 ,并发症发生率为 16.67% ,术后 1、3、5年生存率分别为 70 .0 0 %、2 5 .0 0 %、16.67%。结论 心包内处理血管的全肺切除术是安全的 ,可提高中心型肺癌切除率 ,改善生活质量 ,值得在临床上推广应用。
出处 《右江民族医学院学报》 2004年第6期861-862,共2页 Journal of Youjiang Medical University for Nationalities
  • 相关文献

参考文献6

二级参考文献35

  • 1[1]Albain KS, Pass HI. Induction therapy before surgery for non-small cell lung cancer. Lung Cancer,2000,29(Suppl 2)∶168-171. 被引量:1
  • 2[2]Saito Y, Minami K, Kobayashi M, et al. Ten year's experience of induction therapy for locally advanced NSCLC: a single institute study. Lung Cancer,2000,29(Suppl 1)∶89. 被引量:1
  • 3[3]De Pierre A, Milleron B, Chevret S, et al. French phase Ⅲ trial of preoperative chemotherapy (PCT) in resectable stage Ⅰ( except T1N0), Ⅱ,ⅢA non-small cell lung cancer (NSCLC). Lung Cancer,2000,29(Suppl 1)∶91. 被引量:1
  • 4[4]Pitz C, Riviere BDI, Beek FV, et al. Phase Ⅱ study of induction chemotherapy in patients with stage ⅢB NSCLC. Lung Cancer, 2000,29(Suppl 1)∶89. 被引量:1
  • 5[5]Abolhoda A, Martin J, Ginsberg RJ, et al. Morbidity and mortality for pulmonary resections in lung cancer after induction treatment. Lung Cancer,2000,29(Suppl 1)∶89. 被引量:1
  • 6[6]Mattson K, Velde T, Krofta K, et al. Early results of an international phase Ⅲ study evaluating Taxotere as neoadjuvant therapy for radically-treatable stage Ⅲ NSCLC. Lung Cancer,2000,29(Suppl 1)∶90. 被引量:1
  • 7[7]Kim J, Shim YM, Kim K, et al. A Phase Ⅱ trial of preoperative concurrent chemoradiotherapy for stage ⅢA non-small cell lung cancer with mediastinal lymph node involvement. Lung Cancer, 2000,29(Suppl 1)∶91. 被引量:1
  • 8[8]Date H, Kiura K, Aoe M, et al. Surgical resection of non-small cell lung cancer with mediastinal lymph node metastases after induction chemotherapy with cisplatin and irinotecan. Lung Cancer, 2000,29(Suppl 1)∶91. 被引量:1
  • 9[9]Betticher DC, Hsu SF, Gauthier Y, et al. Neoadjuvant therapy with Docetaxel (TAX) and cisplatin (Cis) in patients (pts) with non-small cell lung cancer (NSCLC), stage ⅢA, N2 is highly activity with few toxicities. Lung Cancer,2000,29(Suppl 1)∶99. 被引量:1
  • 10[10]Leo F, Solli P, Veronesi G, et al. Pulmonary function changes after induction chemotherapy with cisplatinum and gemcitabin in stage Ⅲ non small cell lung cancer. Any additional risk for surgery? Lung Cancer,2000,29(Suppl 1)∶129. 被引量:1

共引文献122

同被引文献11

引证文献3

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部